Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Published
Published
Guidance, NICE advice and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 active)
Skip to results
Filter by title or keyword
Filter
Last updated date
Last updated date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (2)
Type
(
1 selected
)
Type
Guidance (730)
Guidance programme
(
1 selected
)
Guidance programme
Antimicrobial prescribing guidelines (20)
Cancer service guidelines (8)
Clinical guidelines (222)
COVID-19 rapid guidelines (3)
Diagnostics guidance (47)
Health technology evaluations (15)
Highly specialised technologies guidance (25)
Interventional procedures guidance (592)
Medical technologies guidance (65)
Medicines practice guidelines (5)
NICE guidelines (338)
Public health guidelines (61)
Safe staffing guidelines (2)
Social care guidelines (71)
Technology appraisal guidance (730)
Apply filters
Showing 1 to 10 of 730
Sort by
Date
Title
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Published guidance, NICE advice and quality standards
Title
Reference number
Published
Last updated
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal)
TA938
7 December 2023
7 December 2023
Secukinumab for treating moderate to severe hidradenitis suppurativa
TA935
6 December 2023
6 December 2023
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)
TA936
30 November 2023
30 November 2023
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)
TA933
29 November 2023
29 November 2023
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms
TA934
29 November 2023
29 November 2023
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)
TA932
23 November 2023
23 November 2023
Zanubrutinib for treating chronic lymphocytic leukaemia
TA931
22 November 2023
22 November 2023
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments
TA930
15 November 2023
15 November 2023
Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine
TA928
1 November 2023
1 November 2023
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction
TA929
1 November 2023
1 November 2023
Current page
1
2
3
…
73
Page
1
of
73
Next page
Results per page
10
25
50
All
Back to top